{"organizations": [], "uuid": "569e2a6086c8d3309898f36079829f4b4f604fcf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/02/27/the-associated-press-depomed-reports-4q-loss.html", "country": "US", "domain_rank": 767, "title": "Depomed reports 4Q loss", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-27T23:53:00.000+02:00", "replies_count": 0, "uuid": "569e2a6086c8d3309898f36079829f4b4f604fcf"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/02/27/the-associated-press-depomed-reports-4q-loss.html", "ord_in_thread": 0, "title": "Depomed reports 4Q loss", "locations": [], "entities": {"persons": [], "locations": [{"name": "newark", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "newark", "sentiment": "none"}], "organizations": [{"name": "depomed inc.", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEWARK, Calif. (AP) _ Depomed Inc. (DEPO) on Tuesday reported a loss of $33.1 million in its fourth quarter.\nOn a per-share basis, the Newark, California-based company said it had a loss of 52 cents. Earnings, adjusted for non-recurring costs and pretax expenses, were 15 cents per share.\nThe results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 9 cents per share.\nThe drugmaker posted revenue of $94.4 million in the period.\nFor the year, the company reported that its loss widened to $102.5 million, or $1.63 per share. Revenue was reported as $380.7 million.\nDepomed shares have declined almost 5 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $7.67, a fall of 54 percent in the last 12 months.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on DEPO at https://www.zacks.com/ap/DEPO", "external_links": [], "published": "2018-02-27T23:53:00.000+02:00", "crawled": "2018-02-28T01:27:47.000+02:00", "highlightTitle": ""}